Get the Stockscreener App
89.17
2.28%
-2.08
Pre-market:
89.37
0.20
+0.22%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $89.17, with a volume of 11.89M.
It is down -2.28% in the last 24 hours and up +5.75% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$91.25
Open:
$91.32
24h Volume:
11.89M
Relative Volume:
0.94
Market Cap:
$155.32B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
24.84
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
+2.51%
1M Performance:
+5.75%
6M Performance:
-27.24%
1Y Performance:
-33.52%
1-Day Range:
$88.69
$91.32
1-Week Range:
$88.69
$92.73
52-Week Range:
$81.97
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
89.17 | 155.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
308.84 | 118.40B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.25 | 103.03B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
48.34 | 71.85B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.98 | 49.51B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
This is Why Abbott Laboratories (ABT) is One of the Best Deep Value Stock to Invest In - Yahoo Finance
Abbott Offered Faulty Health Plan Option, Ex-Worker Says - Law360
Abbott Diabetes And Cancer Milestones Contrast With Prolonged Share Price Weakness - Yahoo Finance
Abbott (ABT) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Abbott office in Easton part of multi-state portfolio sale - The Business Journals
Abbott Laboratories Hit With Lawsuit Over Healthcare Costs (1) - Bloomberg Law News
Abbott Defeats Account Manager’s Sexualized Workplace Claim - Bloomberg Law News
Mounting Evidence Backs Abbott's Cancer Diagnostics Growth Story - Yahoo Finance
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
BSX, MDT Top Abbott Laboratories Stock on Price & Potential - Trefis
Abbott Laboratories: A Better Than 5 Years AgoBut Still Not A Buy - Seeking Alpha
3 Large Cap Defensive Dividend Stocks With Underestimated Payout Power - simplywall.st
Abbott (ABT) Secures CE Mark for World’s First Dual Glucose‑Ketone Sensing Technology for Diabetes - Insider Monkey
Abbott Laboratories stock (US0028241000): New filing, modest gain, and valuation focus - AD HOC NEWS
Abbott Laboratories stock (US0028241000): analysts stay positive as new diabetes data and steady gai - AD HOC NEWS
Abbott Laboratories price gives in to negative pressureForecast today09-06-2026 - Economies.com
ABT DCF Analysis: Intrinsic Value $93 vs Price $90 - GuruFocus
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $109 - Moomoo
Richard W. Allen Sells Shares in Abbott Laboratories, Ameriprise Financial and More - Investing.com Nigeria
Similac baby formula maker sued by Allegheny County parents over infant’s 2011 death - TribLIVE.com
Abbott Laboratories, maker of Similac baby formula, sued by Allegheny County parents over infant’s 2011 death - TribLIVE.com
Governor Abbott, Secretary Rollins Update Texans On Screwworm Response At Kerrville Lab - Office of the Texas Governor (.gov)
Abbott's Healthy Food Rx Program Shows Promising Results for Dia - GuruFocus
Is It Time To Revisit Abbott Laboratories (ABT) After This Year’s Share Price Slump? - Yahoo Finance
Can Beyond Meat's Pivot to Protein Drinks Change the Investment Thesis? - The Motley Fool
Goldman Sachs Maintains Buy Rating on Abbott Laboratories (ABT) Stock - Insider Monkey
LIVE: Abbott activates emergency center for screwworm response, USDA says 2 more Texas cases - KLBK
BofA Securities Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $120 - 富途牛牛
Abbott activates emergency center for screwworm response, USDA says 2 more Texas cases - KXAN Austin
Food boxes and coaches tied to better diabetes health, less food insecurity - Stock Titan
Abbott Laboratories (ABT) Up 6.4% Following European CE Mark Approval of Dual Glucose-Ketone Sensors - Meyka
Abbott Buy Rating Reaffirmed as Analyst Sees Accelerating 2027 Earnings; $120 Price Target Maintained on Libre Duo Growth Potential - TipRanks
Abbott Laboratories (ABT) Investor Outlook: Harnessing A 28.79% Potential Upside - DirectorsTalk Interviews
Abbott (ABT) Highlights Dangers of Diabetic Ketoacidosis in New Research Findings - GuruFocus
Abbott Laboratories (ABT) Is Up 6.4% After European Approval of Dual Glucose‑Ketone Sensors - simplywall.st
Abbott studies reinforce DKA opportunity following dual sensor milestone - Drug Delivery Business
Abbott reports rising DKA hospitalizations among diabetics - Investing.com
Kids’ diabetes hospital stays now mostly from ketoacidosis, Abbott finds - Stock Titan
Abbott Laboratories slammed on its post-Exact Sciences guidance - MSN
ABT Stock Quote Price and Forecast - CNN
Abbott Says Timing Mismatch Lets $8B Gain Go Untaxed - Law360
What is Abbott Tokenized Stock (Ondo)(ABTON) Coin? A comprehensive guide you shouldn’t miss - WEEX
A Grandma Bought PediaSure To Help Her Grandson Grow — Now, Abbott Is In Federal Court - Benzinga
Abbott Laboratories stock is getting decimated, but the smart money senses opportunity - MSN
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
Is It Too Late to Buy Abbott Laboratories (ABT) After 4.4% Rally? GF Value Says Undervalued - GuruFocus
Judge Questions Fees In Abbott Investors' $40M Formula Deal - Law360
Abbott Can’t Drop PediaSure Children’s Growth Deception Suit - Bloomberg Law News
Abbott Labs must face lawsuit over PediaSure children's growth claims - Reuters
Abbott Labs must face lawsuit over PediaSure children’s growth claims - The Mighty 790 KFGO
Abbott Laboratories Stock (ABT) Closed Up by 4.18% on Jun 4: Drivers Behind the Movement - TradingKey
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):